about
Multidimensional assessment and tailored interventions for COPD: respiratory utopia or common sense?Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities.Distinguishing adult-onset asthma from COPD: a review and a new approach.Use of cluster analysis to describe desaturator phenotypes in COPD: correlations between pulmonary function tests and nocturnal oxygen desaturationFunctional characterization of the matrix metalloproteinase-1 cigarette smoke-responsive region and association with the lung health studyManaging older patients with coexistent asthma and chronic obstructive pulmonary disease: diagnostic and therapeutic challenges.The independent and combined effects of lifetime smoke exposures and asthma as they relate to COPD.The place of inhaled corticosteroids in the treatment of chronic obstructive pulmonary disease: a narrative review.Integral Health Status-Based Cluster Analysis in Moderate-Severe COPD Patients Identifies Three Clinical Phenotypes: Relevant for Treatment As Usual and Pulmonary Rehabilitation.Clinical and functional differences between early-onset and late-onset adult asthma: a population-based Tasmanian Longitudinal Health Study.Diagnostic value of oral prednisolone test for chronic obstructive pulmonary disorders.Understanding the true burden of COPD: the epidemiological challenges.Overlap syndrome of asthma and COPD predicts low quality of life.Natural history of COPD: gaps and opportunities.The association between childhood asthma and adult chronic obstructive pulmonary disease.Subphenotypes of mild-to-moderate COPD by factor and cluster analysis of pulmonary function, CT imaging and breathomics in a population-based survey.High hospital burden in overlap syndrome of asthma and COPD.The rapid FEV(1) decline in chronic obstructive pulmonary disease is associated with predominant emphysema: a longitudinal study.Clinical phenotypes of obstructive airway diseases in an outpatient population.Bronchodilation and Smoking Interaction in COPD: A Cohort Pilot Study to Assess Cardiovascular RiskInhibition of C-X-C Motif Chemokine 10 (CXCL10) Protects Mice from Cigarette Smoke-Induced Chronic Obstructive Pulmonary Disease
P2860
Q27025554-9F60DC6B-3BEF-48AC-BD20-C64BC2577FA0Q33706037-38957D1F-D410-499B-8D80-2EBE435484D7Q34198033-6E4B2B45-948A-4273-9A8C-42C1FEBB9FFBQ35574530-4EFC2235-2D3B-4BF6-B426-6EF7CF322177Q36430685-441FFBFE-E040-4A1A-A19E-F72C1A8E99E9Q38066413-1DA4DB16-3C47-4EF1-881D-FDE97E830401Q38212257-03166373-6D0F-4EEE-AC2F-E09D0A0DFA93Q38827675-9D3BA8E9-F881-467F-AFD8-BAD8AECCC645Q39084879-2A65A3F9-47AD-4AC7-98DD-D8123109AE1AQ39683513-5A0D474D-104C-4366-AF3C-BF1F85DF7FC6Q42686699-8BA1BB41-3A50-471E-BB00-98A9C393DD03Q43819350-C09461ED-1B8F-4A29-B9B3-EA216D6F97E6Q44065053-A1FD9C3D-8697-4670-A0E1-3BF6C5EB1A8EQ47120721-C255C564-82BE-4D39-90E8-A91CFDD4199DQ48118694-ADCCD627-8B5F-40DF-A906-1C815DA1CB46Q48624092-96F36E6C-A0FF-4AEA-803F-676AB2E59BDDQ53116827-EF3270A2-4054-4554-AF64-D9D45CE950C4Q53126886-3B684877-3DA7-402E-A349-80B918C788EAQ53790253-CECA58A3-EBEE-497D-A2E1-A7768548D6CEQ57313528-E6FD6AF2-25B1-4A2A-BFC0-5AE008BD5BB2Q58769047-FD681B7C-CA39-491D-A16F-491E53BFEE8F
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Time to define the disorders of the syndrome of COPD.
@en
Time to define the disorders of the syndrome of COPD.
@nl
type
label
Time to define the disorders of the syndrome of COPD.
@en
Time to define the disorders of the syndrome of COPD.
@nl
prefLabel
Time to define the disorders of the syndrome of COPD.
@en
Time to define the disorders of the syndrome of COPD.
@nl
P1433
P1476
Time to define the disorders of the syndrome of COPD.
@en
P2093
Mark Weatherall
Philippa Shirtcliffe
P304
P356
10.1016/S0140-6736(09)61541-5
P407
P577
2009-08-01T00:00:00Z